Juby A Jacob-Nara
Overview
Explore the profile of Juby A Jacob-Nara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Castro M, Papi A, Porsbjerg C, Lugogo N, Brightling C, Gonzalez-Barcala F, et al.
Lancet Respir Med
. 2025 Feb;
13(3):208-220.
PMID: 39947221
Background: Asthma is a respiratory disease characterised by chronic airway inflammation and mucus hypersecretion. VESTIGE used functional respiratory imaging to assess changes in airway structure and function, including mucus plugging,...
2.
Celli B, Christenson S, Christenson S, Rabe K, Han M, van den Berge M, et al.
Am J Respir Crit Care Med
. 2025 Feb;
PMID: 39938077
Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition of the lungs, characterized by chronic respiratory symptoms, primarily dyspnea, cough, and sputum production, due to airway and/or alveoli abnormalities that...
3.
Bredenoord A, Dellon E, Schlag C, Cianferoni A, Xia C, Pela T, et al.
Expert Rev Gastroenterol Hepatol
. 2025 Feb;
19(2):197-209.
PMID: 39909733
Background: Standard treatments for eosinophilic esophagitis (EoE) may present adherence, tolerance, and efficacy challenges. Dupilumab 300 mg weekly is approved for the treatment of EoE in patients ≥ 1 year...
4.
Wechsler M, Rogers L, Canonica G, Bourdin A, Altincatal A, Hardin M, et al.
ERJ Open Res
. 2024 Dec;
10(6).
PMID: 39687390
https://bit.ly/3XSwX62.
5.
Lugogo N, Soler X, Gon Y, Cote A, Hilberg O, Xia C, et al.
Adv Ther
. 2024 Dec;
42(2):849-862.
PMID: 39652256
Introduction: Patients with uncontrolled, moderate-to-severe asthma have a higher risk for exacerbations, negatively impacting lung function and quality of life. Dupilumab, a fully human monoclonal antibody, blocks interleukins 4 and...
6.
Busse W, Pavord I, Wechsler M, Davila I, Altincatal A, de Prado Gomez L, et al.
Chest
. 2024 Dec;
PMID: 39631682
No abstract available.
7.
Celli B, Anzueto A, Singh D, Hanania N, Fabbri L, Martinez F, et al.
Chest
. 2024 Dec;
PMID: 39631681
Topic Importance: COPD is a complex, heterogeneous lung disease characterized by persistent airflow limitation secondary to airways and parenchymal abnormalities, and respiratory symptoms, including dyspnea, fatigue, chronic cough, and sputum...
8.
Lane A, Mullol J, Hopkins C, Fokkens W, Lee S, Msihid J, et al.
Curr Med Res Opin
. 2024 Dec;
41(1):53-59.
PMID: 39618256
Objective: Loss of sense of smell is a cardinal symptom of chronic rhinosinusitis with nasal polyps (CRSwNP) and significantly impacts health-related quality-of-life. Dupilumab significantly improved smell outcomes (loss of smell...
9.
Jackson D, Hamelmann E, Roberts G, Bacharier L, Xia C, Gall R, et al.
J Allergy Clin Immunol Pract
. 2024 Nov;
13(3):568-575.
PMID: 39613097
Background: Elevated blood or tissue eosinophils are considered to characterize type 2 inflammation in children with asthma and are associated with increased exacerbation rates and worse asthma control. Dupilumab, a...
10.
Pavord I, Rabe K, Israel E, Szefler S, Brusselle G, Pandit-Abid N, et al.
J Allergy Clin Immunol Pract
. 2024 Oct;
13(1):132-142.
PMID: 39424189
Background: Remission is proposed as a multicomponent outcome for patients with severe asthma. Objective: This post hoc analysis of QUEST (NCT02414854) and TRAVERSE (NCT02134028) evaluated whether dupilumab treatment leads to...